Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.
BIOMARKERS
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
POLYARTERITIS NODOSA
TAKAYASU ARTERITIS
VASCULITIS
Journal
The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
accepted:
16
08
2019
pubmed:
3
9
2019
medline:
1
9
2021
entrez:
3
9
2019
Statut:
ppublish
Résumé
We evaluated potential circulating biomarkers of disease activity in giant cell arteritis (GCA), Takayasu arteritis (TA), polyarteritis nodosa (PAN), and eosinophilic granulomatosis with polyangiitis (EGPA). A panel of 22 serum proteins was tested in patients enrolled in the Vasculitis Clinical Research Consortium Longitudinal Studies of GCA, TA, PAN, or EGPA. Mixed models were used for most analyses. A J48 classification tree method was used to find the most relevant markers to differentiate between active and inactive GCA. Tests were done on 418 samples from 152 patients (60 GCA, 29 TA, 26 PAN, 37 EGPA), during both active vasculitis and remission. In GCA, these showed significant (p < 0.05) differences between disease states: B cell-attracting chemokine 1 (BCA)-1/CXC motif ligand 13 (CXCL13), erythrocyte sedimentation rate (ESR), interferon-γ-induced protein 10/CXC motif chemokine 10, soluble interleukin 2 receptor α (sIL-2Rα), and tissue inhibitor of metalloproteinase-1 (TIMP-1). In EGPA, these showed significant increases during active disease: granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF, interleukin (IL)-6, IL-15, and sIL-2Rα. BCA-1/CXCL13 also showed such increases, but only after adjustment for treatment. In PAN, ESR and matrix metalloprotease (MMP)-3 showed significant differences between disease states. Differences in biomarker levels between diseases were significant for 11 markers and were more striking (all p < 0.01) than differences related to disease activity. A combination of lower values of TIMP-1, IL-6, interferon-γ, and MMP-3 correctly classified 87% of samples with inactive GCA. We identified novel biomarkers of disease activity in GCA and EGPA. Differences of biomarker levels between diseases, independent of disease activity, were more apparent than differences related to disease activity. Further studies are needed to determine whether these serum proteins have potential for clinical use in distinguishing active disease from remission or in predicting longer-term outcomes.
Identifiants
pubmed: 31474593
pii: jrheum.190093
doi: 10.3899/jrheum.190093
pmc: PMC7050393
mid: NIHMS1537684
doi:
Substances chimiques
Biomarkers
0
Tissue Inhibitor of Metalloproteinase-1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1001-1010Subventions
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : NIAMS NIH HHS
ID : RC1 AR058303
Pays : United States
Organisme : NIAMS NIH HHS
ID : P60 AR047785
Pays : United States
Organisme : NCRR NIH HHS
ID : U54 RR019497
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072571
Pays : United States
Organisme : NIAMS NIH HHS
ID : U54 AR057319
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Int J Cardiol. 2012 Apr 19;156(2):236-8
pubmed: 22330005
Nat Rev Rheumatol. 2014 Aug;10(8):484-93
pubmed: 24980139
Rheumatology (Oxford). 2015 Aug;54(8):1351-9
pubmed: 25406357
Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i37-i47
pubmed: 28087591
Circulation. 1999 Jul 6;100(1):55-60
pubmed: 10393681
Semin Arthritis Rheum. 2012 Jun;41(6):866-71
pubmed: 22119103
Cephalalgia. 2008 Feb;28(2):157-63
pubmed: 18197885
Nat Rev Immunol. 2004 Sep;4(9):665-74
pubmed: 15343366
Rheumatology (Oxford). 2006 May;45(5):545-8
pubmed: 16352633
PLoS One. 2015 Mar 26;10(3):e0121737
pubmed: 25812008
Arthritis Rheum. 1990 Aug;33(8):1122-8
pubmed: 2202311
Braz J Med Biol Res. 2007 May;40(5):621-31
pubmed: 17464423
Ann Rheum Dis. 2016 Sep;75(9):1583-94
pubmed: 27338776
Rheumatology (Oxford). 2009 Nov;48(11):1460-1
pubmed: 19736181
Arthritis Rheum. 1990 Aug;33(8):1129-34
pubmed: 1975175
Curr Opin Rheumatol. 2014 Jan;26(1):24-30
pubmed: 24257367
Rheumatology (Oxford). 2005 Mar;44(3):309-13
pubmed: 15572394
Rheumatology (Oxford). 2011 Apr;50(4):643-5
pubmed: 20647295
Ann Hematol. 2017 Aug;96(8):1241-1251
pubmed: 28497365
J Rheumatol. 2011 Jun;38(6):1048-54
pubmed: 21411717
Ann Rheum Dis. 2007 Nov;66(11):1429-35
pubmed: 17502363
Int J Cardiol. 1998 Oct 1;66 Suppl 1:S191-4; discussion S195
pubmed: 9951819
J Rheumatol. 2013 May;40(5):674-83
pubmed: 23547217
Rheumatology (Oxford). 2015 Aug;54(8):1397-402
pubmed: 25724206
Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S23-8
pubmed: 14740424
Arthritis Rheum. 1990 Aug;33(8):1094-100
pubmed: 2202307
RMD Open. 2017 Dec 22;3(2):e000570
pubmed: 29299342
Ann Rheum Dis. 2013 Aug;72(8):1342-50
pubmed: 22975753
Ann Rheum Dis. 2014 Mar;73(3):616-23
pubmed: 23625984
J Rheumatol. 2013 Nov;40(11):1905-12
pubmed: 23908447
J Immunol. 2009 Feb 1;182(3):1541-7
pubmed: 19155502
Circulation. 2005 Jul 12;112(2):264-9
pubmed: 15998676
Autoimmun Rev. 2018 Feb;17(2):188-194
pubmed: 29196244